Fig. 4: In vitro activity of AETX-R114 in sotorasib-resistant cell lines. | Nature Communications

Fig. 4: In vitro activity of AETX-R114 in sotorasib-resistant cell lines.

From: Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy

Fig. 4

a–d Incucyte analysis of AETX-R114-induced T cell cytotoxicity against cell lines endogenously expressing KRASG12C in the presence of sotorasib (soto) or vehicle (DMSO). Cell lines were plated in 2D (a–c) or as 3D spheroids (d) with a 10:1 E:T ratio of activated human T cells, and cytotoxicity was assessed at 48 h. Data points represent the mean of 3 technical replicates per condition; error bars indicate SD. The same color scheme applies in all panels. a T cell cytotoxicity from donor ID 110044729, representative of results obtained from 5 independent donors summarized in Supplementary Table 2. b Representative Incucyte images corresponding to the cytotoxicity assay shown in (a). c T cell cytotoxicity from NCI-H2122 HLA isogenic cell lines treated with 10 nM AETX-RSV or AETX-R114. A two-way ANOVA using Šidák’s multiple comparisons test was applied to sotorasib + AETX-RSV and sotorasib + AETX-R114 conditions across cell lines (ns not significant or P > 0.05). d T cell cytotoxicity from donor ID RG1200.

Back to article page